Ser69

Site Information
sGHGsRNsQLGIFss SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 474513
Available spectra: 3 CST

In vivo Characterization
Methods used to characterize site in vivo:	immunoassay ( 3 ) , immunoprecipitation ( 1 , 2 , 5 ) , mass spectrometry ( 1 , 2 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 19 , 20 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 , 3 , 4 , 5 ) , western blotting ( 1 , 4 )
Disease tissue studied:	breast cancer ( 8 ) , breast cancer, triple negative ( 8 ) , cervical cancer ( 5 , 27 ) , cervical adenocarcinoma ( 5 , 27 ) , lung cancer ( 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ) , non-small cell lung cancer ( 11 , 12 , 14 , 15 , 16 , 19 , 20 ) , non-small cell lung adenocarcinoma ( 11 , 12 , 13 , 14 , 15 , 16 , 17 , 20 ) , non-small cell large cell lung carcinoma ( 12 , 14 ) , non-small cell squamous cell lung carcinoma ( 13 ) , small-cell lung cancer ( 9 , 10 ) , melanoma skin cancer ( 6 )
Relevant cell line - cell type - tissue:	'stem, embryonic' ( 29 ) , A549 (pulmonary) ( 11 ) , breast ( 8 ) , Cal-12T (pulmonary) ( 16 ) , DMS153 (pulmonary) ( 15 ) , DMS53 (pulmonary) ( 10 ) , DMS79 (pulmonary) ( 9 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 22 ) , Flp-In T-Rex-293 (epithelial) ( 22 ) , HCC15 (pulmonary) ( 13 ) , HCC44 (pulmonary) ( 16 ) , HCC78 (pulmonary) ( 14 ) , HeLa (cervical) ( 1 , 2 , 4 , 7 , 21 , 26 , 30 ) , HeLa K (cervical) ( 5 ) , HeLa S3 (cervical) [PLK1 (human), knockdown, Tet-inducible PLK1 siRNA] ( 25 ) , HeLa S3 (cervical) ( 25 , 27 , 28 ) , LOU-NH91 (squamous) ( 13 ) , lung ( 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ) , NCI-H128 (pulmonary) ( 9 ) , NCI-H1299 (pulmonary) ( 12 ) , NCI-H1355 (pulmonary) ( 11 ) , NCI-H1417 (pulmonary) ( 9 ) , NCI-H1437 (pulmonary) ( 15 , 16 ) , NCI-H1666 (pulmonary) ( 16 ) , NCI-H1703 (squamous) ( 13 ) , NCI-H1734 (pulmonary) ( 12 ) , NCI-H1781 (pulmonary) ( 14 ) , NCI-H1792 (pulmonary) ( 11 ) , NCI-H1944 (pulmonary) ( 12 ) , NCI-H2073 (pulmonary) ( 13 , 15 ) , NCI-H209 (pulmonary) ( 9 , 15 ) , NCI-H2228 (pulmonary) ( 14 , 20 ) , NCI-H23 (pulmonary) ( 11 ) , NCI-H2342 (pulmonary) ( 13 ) , NCI-H2405 (pulmonary) ( 16 ) , NCI-H3122 (pulmonary) ( 14 , 19 ) , NCI-H358 (pulmonary) ( 12 ) , NCI-H441 (pulmonary) ( 11 ) , NCI-H446 (pulmonary) ( 10 ) , NCI-H460 (pulmonary) ( 12 ) , NCI-H524 (pulmonary) ( 9 ) , NCI-H526 (pulmonary) ( 10 ) , NCI-H661 (pulmonary) ( 14 ) , NCI-H69 (pulmonary) ( 10 ) , NCI-H82 (pulmonary) ( 10 ) , NCI-H838 (pulmonary) ( 15 ) , PtK1 (epithelial) ( 5 ) , RPE-1 (retinal) ( 3 , 4 ) , WM239A (melanocyte) ( 6 )

Upstream Regulation
Regulatory protein:	INCENP (human) ( 4 , 5 ) , PPP6C (human) ( 1 ) , TPX2 (human) ( 1 , 5 ) , TRAF4AF1 (human) ( 3 )
Putative in vivo kinases:	AurA (human) ( 1 , 4 )
Kinases, in vitro:	AurA (human) ( 5 ) , AurB (human) ( 5 , 31 )
Treatments:	AZD1152 ( 1 ) , BTB-1 ( 4 ) , MLN8054 ( 5 , 26 ) , MLN8237 ( 1 ) , nocodazole ( 1 , 2 , 5 ) , siRNA ( 1 ) , STLC ( 2 ) , TAME ( 2 ) , taxol ( 5 ) , UMK57 ( 4 ) , ZM447439 ( 1 , 5 )

Downstream Regulation
Effects of modification on biological processes:	cell cycle regulation ( 1 , 5 , 31 ) , cytoskeletal reorganization ( 2 )

References
1	Sobajima T, et al. (2023) PP6 regulation of Aurora A-TPX2 limits NDC80 phosphorylation and mitotic spindle size. J Cell Biol 222 36897279 Curated Info
2	Kucharski TJ, et al. (2022) Small changes in phospho-occupancy at the kinetochore-microtubule interface drive mitotic fidelity. J Cell Biol 221 35878017 Curated Info
3	Rosas-Salvans M, Sutanto R, Suresh P, Dumont S (2022) The Astrin-SKAP complex reduces friction at the kinetochore-microtubule interface. Curr Biol 32, 2621-2631.e3 35580605 Curated Info
4	Iemura K, et al. (2021) Chromosome oscillation promotes Aurora A-dependent Hec1 phosphorylation and mitotic fidelity. J Cell Biol 220 33988677 Curated Info
5	DeLuca KF, et al. (2018) Aurora A kinase phosphorylates Hec1 to regulate metaphase kinetochore-microtubule dynamics. J Cell Biol 217, 163-177 29187526 Curated Info
6	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
7	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
8	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
9	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
10	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
11	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
12	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
13	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
14	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
15	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
16	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
17	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
18	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
19	Rikova K (2013) CST Curation Set: 18503; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
20	Rikova K (2013) CST Curation Set: 18502; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
21	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
22	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
23	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
24	Rikova K (2012) CST Curation Set: 13736; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (SQ) Immunoaffinity Beads Cat#: 9884 Curated Info
25	Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457 20860994 Curated Info
26	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
27	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
28	Malik R, et al. (2009) Quantitative analysis of the human spindle phosphoproteome at distinct mitotic stages. J Proteome Res 8, 4553-63 19691289 Curated Info
29	Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13 19664994 Curated Info
30	Zhou J (2009) CST Curation Set: 6241; Year: 2009; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980 Curated Info
31	DeLuca JG, et al. (2006) Kinetochore microtubule dynamics and attachment stability are regulated by Hec1. Cell 127, 969-82 17129782 Curated Info